메뉴 건너뛰기




Volumn 33, Issue 23, 2015, Pages 2563-2577

American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options

(24)  Schnipper, Lowell E a   Davidson, Nancy E e   Wollins, Dana S g   Tyne, Courtney g   Blayney, Douglas W h   Blum, Diane d   Dicker, Adam P f   Ganz, Patricia A i   Hoverman, J Russell l   Langdon, Robert d   Lyman, Gary H m   Meropol, Neal J n   Mulvey, Therese d   Newcomer, Lee o   Peppercorn, Jeffrey b   Polite, Blase p   Raghavan, Derek d   Rossi, Gregory q   Saltz, Leonard k   Schrag, Deborah c   more..


Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

EID: 84939251874     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.6706     Document Type: Article
Times cited : (773)

References (58)
  • 1
    • 79251470391 scopus 로고    scopus 로고
    • Projections of the cost of cancer care in the United States: 2010-2020
    • Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
    • (2011) J Natl Cancer Inst , vol.103 , pp. 117-128
    • Mariotto, A.B.1    Yabroff, K.R.2    Shao, Y.3
  • 3
    • 84890150950 scopus 로고    scopus 로고
    • Access, affordability, and insurance complexity are often worse in the United States compared to 10 other countries
    • Schoen C, Osborn R, Squires D, et al: Access, affordability, and insurance complexity are often worse in the United States compared to 10 other countries. Health Aff (Millwood) 32:2205-2215, 2013
    • (2013) Health Aff (Millwood) , vol.32 , pp. 2205-2215
    • Schoen, C.1    Osborn, R.2    Squires, D.3
  • 5
    • 84891686782 scopus 로고    scopus 로고
    • Delivering high-quality and affordable care throughout the cancer care continuum
    • Shih YT, Ganz PA, Aberle D, et al: Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol 31:4151-4157, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 4151-4157
    • Shih, Y.T.1    Ganz, P.A.2    Aberle, D.3
  • 6
    • 84867828250 scopus 로고    scopus 로고
    • Patients' expectations about effects of chemotherapy for advanced cancer
    • Weeks JC, Catalano PJ, Cronin A, et al: Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616-1625, 2012
    • (2012) N Engl J Med , vol.367 , pp. 1616-1625
    • Weeks, J.C.1    Catalano, P.J.2    Cronin, A.3
  • 7
    • 84879256683 scopus 로고    scopus 로고
    • Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis
    • Ramsey S, Blough D, Kirchhoff A, et al: Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32:1143-1152, 2013
    • (2013) Health Aff (Millwood) , vol.32 , pp. 1143-1152
    • Ramsey, S.1    Blough, D.2    Kirchhoff, A.3
  • 8
    • 84876486250 scopus 로고    scopus 로고
    • Financial toxicity, part 1: A new name for a growing problem
    • Zafar SY, Abernathy AP: Financial toxicity, part 1: A new name for a growing problem. Oncology (Williston Park) 27:80-81, 149, 2013
    • (2013) Oncology (Williston Park) , vol.27
    • Zafar, S.Y.1    Abernathy, A.P.2
  • 9
    • 80052695744 scopus 로고    scopus 로고
    • Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
    • Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 7:46s-51s, 2011 (suppl)
    • (2011) J Oncol Pract , vol.7 , pp. 46s-51s
    • Streeter, S.B.1    Schwartzberg, L.2    Husain, N.3
  • 10
    • 84925333002 scopus 로고    scopus 로고
    • Population-based assessment of cancer survivors' financial burden and quality of life: A prospective cohort study
    • Zafar SU, McNeil RB, Thomas CM, et al: Population-based assessment of cancer survivors' financial burden and quality of life: A prospective cohort study. J Oncol Pract 11:145-150, 2015
    • (2015) J Oncol Pract , vol.11 , pp. 145-150
    • Zafar, S.U.1    McNeil, R.B.2    Thomas, C.M.3
  • 11
    • 84874631714 scopus 로고    scopus 로고
    • The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience
    • Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381-390, 2013
    • (2013) Oncologist , vol.18 , pp. 381-390
    • Zafar, S.Y.1    Peppercorn, J.M.2    Schrag, D.3
  • 12
    • 84940531023 scopus 로고    scopus 로고
    • Provider-patient communication about cost of care: Results from a national patient education program
    • Ahmed IA, Harvey A, Amsellem M, et al: Provider-patient communication about cost of care: Results from a national patient education program. J Clin Oncol 31:594s, 2013 (suppl 15; abstr 9578)
    • (2013) J Clin Oncol , vol.31 , pp. 594s
    • Ahmed, I.A.1    Harvey, A.2    Amsellem, M.3
  • 13
    • 0042697034 scopus 로고    scopus 로고
    • Patient-physician communication about out-of-pocket costs
    • Alexander GC, Casalino LP, Meltzer DO: Patient-physician communication about out-of-pocket costs. JAMA 290:953-958, 2003
    • (2003) JAMA , vol.290 , pp. 953-958
    • Alexander, G.C.1    Casalino, L.P.2    Meltzer, D.O.3
  • 14
    • 84919769081 scopus 로고    scopus 로고
    • Debating the oncologist's role in defining the value of cancer care: Our duty is to our patients
    • Sulmasy D, Moy B: Debating the oncologist's role in defining the value of cancer care: Our duty is to our patients. J Clin Oncol 32:4039-4041, 2014
    • (2014) J Clin Oncol , vol.32 , pp. 4039-4041
    • Sulmasy, D.1    Moy, B.2
  • 15
    • 0034890949 scopus 로고    scopus 로고
    • Should physicians be gatekeepers of medical resources?
    • Weinstein MC: Should physicians be gatekeepers of medical resources? J Med Ethics 27:268-274, 2001
    • (2001) J Med Ethics , vol.27 , pp. 268-274
    • Weinstein, M.C.1
  • 16
    • 68949112230 scopus 로고    scopus 로고
    • American Society of Clinical Oncology guidance statement: The cost of cancer care
    • Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 3868-3874
    • Meropol, N.J.1    Schrag, D.2    Smith, T.J.3
  • 17
    • 84863195517 scopus 로고    scopus 로고
    • ASCO identifies five key opportunities to improve care and reduce costs: The top five list for oncology
    • Schnipper LE, Smith TJ, Raghavan D, et al: ASCO identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715-1724, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 1715-1724
    • Schnipper, L.E.1    Smith, T.J.2    Raghavan, D.3
  • 18
    • 84892900404 scopus 로고    scopus 로고
    • American Society of Clinical Oncology 2013 top five list in oncology
    • Schnipper LE, Lyman GH, Blayney DW: American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 31:4362-4370, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 4362-4370
    • Schnipper, L.E.1    Lyman, G.H.2    Blayney, D.W.3
  • 19
    • 84855264223 scopus 로고    scopus 로고
    • Review of the American College of Physicians Ethics Manual: Sixth edition
    • Snyder LS: Review of the American College of Physicians Ethics Manual: Sixth edition. Ann Intern Med 156:73-104, 2012
    • (2012) Ann Intern Med , vol.156 , pp. 73-104
    • Snyder, L.S.1
  • 20
    • 78649948668 scopus 로고    scopus 로고
    • A method for defining value in healthcare using cancer care as a model
    • Feeley TW, Fly HS, Albright H, et al: A method for defining value in healthcare using cancer care as a model. J Healthc Manag 55:399-411, 2010
    • (2010) J Healthc Manag , vol.55 , pp. 399-411
    • Feeley, T.W.1    Fly, H.S.2    Albright, H.3
  • 23
    • 58149092838 scopus 로고    scopus 로고
    • Decision making and quality of life in the treatment of cancer: A review
    • Zafar SY, Alexander SC, Weinfurt KP, et al: Decision making and quality of life in the treatment of cancer: A review. Support Care Cancer 17:117-127, 2009
    • (2009) Support Care Cancer , vol.17 , pp. 117-127
    • Zafar, S.Y.1    Alexander, S.C.2    Weinfurt, K.P.3
  • 24
    • 77954636785 scopus 로고    scopus 로고
    • Beyond costs and benefits: Understanding how patients make health care decisions
    • Ubel PA: Beyond costs and benefits: Understanding how patients make health care decisions. Oncologist 15:5-10, 2010 (suppl 1)
    • (2010) Oncologist , vol.15 , pp. 5-10
    • Ubel, P.A.1
  • 25
    • 77953660030 scopus 로고    scopus 로고
    • Drug pricing and value in oncology
    • Danzon PM, Taylor E: Drug pricing and value in oncology. Oncologist 15:24-31, 2010 (suppl 1)
    • (2010) Oncologist , vol.15 , pp. 24-31
    • Danzon, P.M.1    Taylor, E.2
  • 26
    • 33745959588 scopus 로고    scopus 로고
    • Communication preferences and needs of cancer patients: The importance of content
    • Surbone A: Communication preferences and needs of cancer patients: The importance of content. Support Care Cancer 14:789-791, 2006
    • (2006) Support Care Cancer , vol.14 , pp. 789-791
    • Surbone, A.1
  • 29
    • 33645662113 scopus 로고    scopus 로고
    • Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom
    • Morgan SG, McMahon M, Mitton C, et al: Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff (Millwood) 25:337-347, 2006
    • (2006) Health Aff (Millwood) , vol.25 , pp. 337-347
    • Morgan, S.G.1    McMahon, M.2    Mitton, C.3
  • 31
    • 84940546318 scopus 로고    scopus 로고
    • Scottish Medicines Consortium: Templates/guidelines for submission. https://www.scottishmedicines.org.uk/Submission-Process/Submission-guidance-and-forms/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission
    • Templates/guidelines for Submission
  • 32
    • 84940498675 scopus 로고    scopus 로고
    • All Wales Medicines Strategy Group: Medicines strategy for Wales. http://www.awmsg.org/awmsg-strategy.html
    • Medicines Strategy for Wales
  • 39
    • 84896706532 scopus 로고    scopus 로고
    • Does comparative effectiveness research promote rationing of cancer care?
    • Peppercorn J, Zafar SY, Houck K, et al: Does comparative effectiveness research promote rationing of cancer care? Lancet Oncol. 15:e132-e138, 2014
    • (2014) Lancet Oncol , vol.15 , pp. e132-e138
    • Peppercorn, J.1    Zafar, S.Y.2    Houck, K.3
  • 40
    • 84901630147 scopus 로고    scopus 로고
    • ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines
    • Anderson JL, Heidenreich PA, Barnett PG, et al: ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines. J Am Coll Cardiol 63:2304-2322, 2014
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2304-2322
    • Anderson, J.L.1    Heidenreich, P.A.2    Barnett, P.G.3
  • 41
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-50, 2006
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 42
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 43
    • 0035849269 scopus 로고    scopus 로고
    • Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicenter trial
    • Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicenter trial. Lancet 357:1478-1484, 2001
    • (2001) Lancet , vol.357 , pp. 1478-1484
    • Georgoulias, V.1    Papadakis, E.2    Alexopoulos, A.3
  • 44
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicenter, open-label, randomized phase 3 trial
    • Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicenter, open-label, randomized phase 3 trial. Lancet Oncol 13:239-246, 2012
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 45
    • 84940500451 scopus 로고    scopus 로고
    • UnitedHealthcare
    • UnitedHealthcare
  • 46
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
    • (2008) N Engl J Med , vol.359 , pp. 906-917
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 47
    • 84874768399 scopus 로고    scopus 로고
    • Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
    • San Miguel JF, Schlag R, Khuageva NK, et al: Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31:448-455, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 448-455
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 48
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • De Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 49
    • 84870243969 scopus 로고    scopus 로고
    • Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomized trial
    • Logothetis CJ, Basch E, Molina A, et al: Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomized trial. Lancet Oncol 13:1210-1217, 2012
    • (2012) Lancet Oncol , vol.13 , pp. 1210-1217
    • Logothetis, C.J.1    Basch, E.2    Molina, A.3
  • 50
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial
    • De Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 376:1147-1154, 2010
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 51
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 52
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 53
    • 80052728749 scopus 로고    scopus 로고
    • Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31
    • Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 3366-3373
    • Perez, E.A.1    Romond, E.H.2    Suman, V.J.3
  • 54
    • 80053539103 scopus 로고    scopus 로고
    • Adjuvant trastuzumab in HER2-positive breast cancer
    • Slamon D, Eirmann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
    • (2011) N Engl J Med , vol.365 , pp. 1273-1283
    • Slamon, D.1    Eirmann, W.2    Robert, N.3
  • 55
    • 84899911233 scopus 로고    scopus 로고
    • American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes
    • Ellis LM, Bernstein DS, Voest EE, et al: American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32:1277-1280, 2014
    • (2014) J Clin Oncol , vol.32 , pp. 1277-1280
    • Ellis, L.M.1    Bernstein, D.S.2    Voest, E.E.3
  • 56
    • 0031900689 scopus 로고    scopus 로고
    • Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis
    • Stinnett AA, Mullahy J: Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 12:S68-S80, 1998 (suppl)
    • (1998) Med Decis Making , vol.12 , pp. S68-S80
    • Stinnett, A.A.1    Mullahy, J.2
  • 58
    • 2442562971 scopus 로고    scopus 로고
    • Problems and solutions in calculating quality-adjusted life years (QALYs)
    • Prieto L, Sacristán JA: Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes 1:80, 2003
    • (2003) Health Qual Life Outcomes , vol.1 , pp. 80
    • Prieto, L.1    Sacristán, J.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.